eyeball
eyeball
eyeball
eyeball
eyeball
eyeball
eyeball
eyeball

PATIENT WEBSITE LINK:

https://studykik.com/study-page/wamd-19493-hcp

Study Site Locations

Please contact the site closest to you for study inquiries or to discuss a participant referral.

Search within
Miles of

Australia

Coming Soon

PI Name

Street Address

City, State

Australia

0872

Site Contact Name

Site Contact Phone Number

eye charteye chart

Inclusion and Exclusion Criteria

Participants who meet the following criteria may be eligible to participate: Inclusion • Male or female subjects, ≥50 years of age. • Documented diagnosis of wAMD in the study eye, with onset of disease that began at any time prior to the Screening Visit. • Active subfoveal CNV due to wAMD, including juxtafoveal lesions that affect the fovea, as defined by presence of fluid (intraretinal or subretinal) affecting the central subfield as measured by SD-OCT. Exclusion • CNV caused by ocular histoplasmosis, pathological myopia, angioid streaks, choroidal rupture, uveitis, and trauma. • Fibrosis >50% of the total lesion. This is not a full list of criteria.

eyeball
eyeball
eyeball
eyeball

FAQ’s

What is the primary objective of the EYP-1901-302 study?

To evaluate the efficacy of EYP-1901 intravitreal (IVT) insert on best corrected visual acuity (BCVA) changes compared to aflibercept treatment.

What is the study drug being evaluated in the EYP-1901-302 study?

EYP-1901 (vorolanib intravitreal [IVT] insert)

If my participant qualifies for the EYP-1901-302 study, will they receive the study drug?

Participants will be randomly assigned to one of two treatment groups: EYP-1901 or aflibercept.

How many participants will be in this study?

Approximately 400 participants will be enrolled.